Blue cone monochromacy and gene therapy

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Blue cone monochromacy (BCM) is a congenital visual disorder resulting from mutations in the OPN1LW/OPN1MW gene cluster.
• BCM is characterized by reduced long- and middle-wavelength cone function, leading to poor visual acuity, impaired color vision, myopia, and nystagmus.

Approach:

• This review covers genetic causes, clinical features, diagnostic methods, and outcome measures for BCM.
• Emphasis is placed on detailing animal models and adeno-associated vector (AAV)-mediated gene therapy approaches for BCM.
• Two mouse models mimicking common BCM causes are discussed, alongside progress in gene therapy proof-of-concept studies.

Key Points:

• Genetic mutations in the OPN1LW/OPN1MW gene cluster are the primary cause of BCM.
• Animal models are crucial for understanding BCM pathogenesis and testing therapeutic interventions.
• Adeno-associated vector (AAV) gene therapy shows promise for treating BCM, with ongoing research and development.

Conclusions:

• Further research into BCM animal models and AAV gene therapy is essential for developing effective treatments.
• Clinical outcome measurements are critical for evaluating the efficacy of future BCM therapies.
• Addressing the challenges in gene therapy will pave the way for clinical applications in BCM patients.